Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First‐Line EGFR‐TKIs

[1]  S. Popat,et al.  Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer , 2017, Clinical lung cancer.

[2]  H. Klomp,et al.  Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. , 2017, Lung cancer.

[3]  S. Ren,et al.  Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. , 2017, Journal of thoracic disease.

[4]  Tao Jiang,et al.  Characterization of Liver Metastasis and Its Effect on Targeted Therapy in EGFR‐mutant NSCLC: A Multicenter Study , 2017, Clinical lung cancer.

[5]  M. Qiu,et al.  Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis. , 2017, Journal of thoracic disease.

[6]  S. Gettinger,et al.  Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Lee,et al.  Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study , 2016, The Lancet. Oncology.

[8]  R. Weichselbaum,et al.  Clinical and molecular markers of long‐term survival after oligometastasis‐directed stereotactic body radiotherapy (SBRT) , 2016, Cancer.

[9]  D. Na,et al.  A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  D. Gomez,et al.  Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. , 2014, International journal of radiation oncology, biology, physics.

[11]  D. Gomez,et al.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. , 2014, Clinical lung cancer.

[12]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[13]  F. Hirsch,et al.  The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non–small cell lung cancer , 2014, Cancer.

[14]  Laura W. Christianson,et al.  Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. , 2014, Lung cancer.

[15]  Jingyun Shi,et al.  T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. , 2014, Lung cancer.

[16]  Yi-long Wu,et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. , 2014, The Lancet. Oncology.

[17]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[20]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[21]  S. Hirano,et al.  Role of Radiotherapy for Local Control of Asymptomatic Adrenal Metastasis From Lung Cancer , 2011, American journal of clinical oncology.

[22]  M. Eble,et al.  Stereotactic Body Radiation Therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer , 2011, Strahlentherapie und Onkologie.

[23]  S. Thongprasert,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[24]  R. Weichselbaum,et al.  An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease , 2008, Clinical Cancer Research.

[25]  Jinming Yu,et al.  Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. , 2008, Lung cancer.

[26]  S. Hassenbusch,et al.  Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis , 2006, Cancer.

[27]  G. V. von Schulthess,et al.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.

[28]  P. Iyengar,et al.  Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial , 2018, JAMA oncology.

[29]  Yi-long Wu,et al.  Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. , 2013, Lung cancer.